Some thoughts and observations:
1. After going through the 100 page protocol of the study and the ten year time frame you get the sense that if THIS is what comparative effectiveness research will look like, good luck. It will be a waste of time, money and effort compared to investing in research that attempts to figure out what is the best way to control or prevent disease in individuals.
2. Avandia is redeemed once again in a real world setting, such as it is. As the National Heart Blood and Lung Institute noted: Because of the recent concerns with rosiglitazone (Avandia), which is one of several medications used in ACCORD, researchers specifically reviewed data to determine whether there was any link between this particular medication and the increased deaths. To date, no link has been found. (For more on this issue, see http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=287 .)
3. But don't expect a mea culpa from Steven Nissen, the media or anyone else involved in this sorry story.
4. The Vice Chair of the Accord Steering committee? John Buse, the very same Buse that Senator Grassley and Rosa DeLauro are 'defending' against Dr. Yamada decade old criticism that Buse was way off base about the cardiovascular risks of....Avandia. Who owes who an apology?
5. Oh, The ACCORD trialists adjusted the protocols to ensure the trials met the endpoints. That is, it change how the trial was run to hit the A1C targets. Imagine if a drug company tried to do that!